Immunological Effects of Bevacizumab-Based Treatment in Metastatic Colorectal Cancer

Publisher： Karger

E-ISSN： 1423-0232|79|3-4|187-196

ISSN： 0030-2414

Source： Oncology, Vol.79, Iss.3-4, 2011-02, pp. : 187-196

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Bevacizumab plus Irinotecan-Based Regimens in the Treatment of Metastatic Colorectal Cancer

By  

Oncology, Vol. 79, Iss. 1-2, 2010-11 ,pp. : 118-128

Karger

Access to resources Recommend Favorite

Economic analysis of bevacizumab, cetuximab, and panitumumab with fluoropyrimidine-based chemotherapy in the first-line treatment of KRAS wild-type metastatic colorectal cancer (mCRC)

By Lawrence Donna   Maschio Michael   Leahy Kevin J.   Yunger Simon   Easaw Jacob C.   Weinstein Milton C.  

Journal of Medical Economics, Vol. 16, Iss. 12, 2013-12 ,pp. : 1387-1398

Informa Healthcare

Access to resources Recommend Favorite

Bevacizumab plus Oxaliplatin-Based Regimens for the Treatment of Colorectal Cancer

By  

Oncology Research and Treatment, Vol. 32, Iss. 7, 2009-06 ,pp. : 431-439

Karger

Access to resources Recommend Favorite

Stop and Go FOLFOX plus Bevacizumab Chemotherapy in the First-Line Treatment of Metastatic Colorectal Cancer

By  

Oncology, Vol. 79, Iss. 1-2, 2010-11 ,pp. : 67-71

Karger

Access to resources Recommend Favorite

5-Fluorouracil, Leucovorin and Oxaliplatin plus Bevacizumab in the First-Line Treatment of Metastatic Colorectal Cancer: A Single-Institute Study

By  

Oncology, Vol. 72, Iss. 1-2, 2007-10 ,pp. : 4-9

Karger

Access to resources Recommend Favorite